Gilead’s remdesivir gets MHRA green light, but only targets a select group of Covid-19 patients

2 June 2020 (Last Updated June 2nd, 2020 15:21)

Last week, Gilead's remdesivir received its first positive scientific opinion from the Medicines and Healthcare products Regulatory Agency (MHRA) under the Early Access to Medicines Scheme (EAMS) for use in Covid-19 patients.

GlobalData suspects that remdesivir will target a select severity group of Covid-19 patients, with the question of how it will be best to initiate and optimise treatment of the disease with the drug. Read more here.